Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01637285 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
49
Enrollment target
1
Study location

NCT01637285: Completed Phase 1 study of Healthy, sponsored by Pfizer.

NCT01637285 is a Phase 1 study of Healthy that has completed, run by Pfizer. The registered enrollment target is 49 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01637285, a Phase 1 study of Healthy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

Conditions Studied

Interventions

  • BIOLOGICAL PF-04856883

Study Locations (1)

Connecticut

  • New Haven Clinical Research Unit - New Haven

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2012-08
Est. Completion 2013-01
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT01637285 record still lists

NCT01637285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which PF-04856883 is the first listed.

NCT01637285 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT01637285 about?

NCT01637285 is a clinical study titled "A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers". The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

What is the current status of trial NCT01637285?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-08. Estimated completion is 2013-01.

What conditions does trial NCT01637285 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01637285?

The interventions under investigation include: PF-04856883 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01637285?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01637285 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01637285's enrollment target sits among peer trials

49 474th of 1090 higher than 613 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01637285, the US trial registry maintained by the National Library of Medicine. NCT01637285 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.